SELLAS Life Sciences Group Inc buy Heureka
Start price
27.02.20
/
50%
€2.39
Target price
09.03.20
€3.00
Performance (%)
-23.10%
End price
09.03.20
€1.84
Summary
This prediction ended on 09.03.20 with a price of €1.84. The price of SELLAS Life Sciences Group Inc has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -23.10%. Heureka has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | -6.732% | -6.732% | 601.909% | 578.977% |
| iShares Core DAX® | 0.184% | 5.072% | 8.979% | 63.879% |
| iShares Nasdaq 100 | -0.770% | -2.079% | 26.437% | 88.094% |
| iShares Nikkei 225® | 0.733% | -3.346% | 47.887% | 78.014% |
| iShares S&P 500 | -0.166% | 0.904% | 22.974% | 69.449% |